@article{3220766,
    title = "A real-world, non-interventional, prospective study of the effectiveness and safety of apremilast in bio-naïve adults with moderate plaque psoriasis treated in the routine care in Greece – the ‘APRAISAL’ study",
    author = "Ioannides, D. and Antonakopoulos, N. and Chasapi, V. and Oikonomou, C. and Tampouratzi, E. and Lazaridou, E. and Rigopoulos, D. and Neofotistou, O. and Drosos, A. and Anastasiadis, G. and Rovithi, E. and Kalinou, C. and Papadavid, E. and Aronis, P. and Papageorgiou, M. and Protopapa, A. and Bassukas, I. and Lefaki, I. and Zafiriou, E. and Krasagakis, K. and Pokas, E. and Anagnostopoulos, Z. and Kekki, A. and Papakonstantis, M.",
    journal = "Journal of the European Academy of Dermatology and Venereology",
    year = "2022",
    publisher = "John Wiley and Sons Inc",
    issn = "0926-9959, 1468-3083",
    doi = "10.1111/jdv.18166",
    abstract = "Background: Real-world data in patients with moderate psoriasis treated with apremilast is limited. Objectives: To evaluate the effectiveness and safety of apremilast in bio-naïve patients with moderate psoriasis in real-world clinical settings. Methods: This was a 52-week multicenter, observational, prospective study of adult outpatients with moderate psoriasis {[10% < body surface area < 20% or 10 < psoriasis area severity index (PASI) < 20] and 10 < dermatology quality of life index (DLQI) < 20} initiated on apremilast ≤7 days before enrollment. Missing data were imputed using the last observation carried forward method. Results: A total of 287 eligible patients (median age: 54.2 years; median psoriasis duration: 9.8 years) were consecutively enrolled. At baseline, the median DLQI and PASI scores were 12.0 and 11.8, respectively. The 52-week DLQI ≤ 5 and PASI75 response rates were 68.3% and 61.0%. At 52 weeks, 70.8% and 72.7% of the patients shifted from moderate/severe/very severe to clear/minimal scalp and palmoplantar psoriasis involvement, respectively; the pruritus severity state improved in 67.2%. The 52-week Kaplan–Meier estimated drug continuation rate was 85.3%. The adverse drug reaction rate was 19.9%. Conclusions: Apremilast is a safe and effective treatment for bio-naïve patients with moderate psoriasis and specific psoriasis manifestations. © 2022 European Academy of Dermatology and Venereology."
}